Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases (Q35090145)

6 August 2017

1 reference

title

Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases (English)

1 reference

6 August 2017

Timothy A Stewart

1

1 reference

6 August 2017

1 April 2003

1 reference

Cytokine and Growth Factor Reviews

6 August 2017

1 reference

6 August 2017

14

1 reference

6 August 2017

2

1 reference

6 August 2017

139-154

1 reference

Nomenclature of the human interferon genes.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Potentiation of the action of interferon by extracts of Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of Circulating Interferon by Synthetic Anionic Polymers of Known Composition

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interleukin 2 induces interferon alpha/beta production in mouse bone marrow cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Exogenous interferon-gamma induces endogenous synthesis of interferon-alpha and -beta by murine macrophages for induction of nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction by vasoactive intestinal peptide of interferon alpha/beta synthesis in glial cells but not in neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Functional role of type I and type II interferons in antiviral defense

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Major peptide autoepitopes for nucleosome-specific T cells of human lupus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

T-cell recognition of beta-cell autoantigens in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

T cell responses to type 1 diabetes related peptides sharing homologous regions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

C. L. Oakley lecture (1987). The pathogenesis of beta cell destruction in type I (insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Production of interferon by peritoneal cells of several inbred mouse strains

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Islet expression of interferon-alpha precedes diabetes in both the BB rat and streptozotocin-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of type I diabetes by interferon-alpha in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon-alpha in lupus psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Measurement of intracellular interferon-gamma and interleukin-4 in whole blood T lymphocytes from patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Insulitis in type 1 (insulin-dependent) diabetes mellitus in man--macrophages, lymphocytes, and interferon-gamma containing cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The type I interferon system is locally activated in psoriatic lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon-alpha drives T cell-mediated immunopathology in the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Side effects of high-dose interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Reversible diabetes in patient with AIDS-related Kaposi's sarcoma treated with interferon α-2a

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of insulin antibodies and insulin allergy under alpha-interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus--a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Psoriasis induced by interferon-α

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Severe Raynaud's syndrome associated with interferon therapy. A case history

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Myasthenia gravis during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Virus interference. I. The interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of interferon synthesis by synthetic double-stranded polynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

HN proteins of human parainfluenza type 4A virus expressed in cell lines transfected with a cloned cDNA have an ability to induce interferon in mouse spleen cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon production by the spleen of rats after intravenous injection of Sindbis virus or heat-killed Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Endogenous retroviruses in systemic lupus erythematosus: candidate lupus viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Systemic lupus erythematosus--is a viral aetiology a credible hypothesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of interferon-alpha by interferon-beta, but not of interferon-beta by interferon-alpha, in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Immunoglobulin from systemic lupus erythematosus serum induces interferon release by normal mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Effect of interferon on early interferon production

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Mouse and human dendritic cell subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The nature of the principal type 1 interferon-producing cells in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Type I interferons produced by dendritic cells promote their phenotypic and functional activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Type I interferons keep activated T cells alive

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Induction of bystander T cell proliferation by viruses and type I interferon in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Type I interferon-mediated stimulation of T cells by CpG DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon α

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The influence of interferon alpha and gamma, singly or in combination on human natural cell mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Enhancement of monocyte-mediated tumoricidal activity by multiple interferon-alpha species

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Influence of interferon on human monocyte to macrophage development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Natural human interferon-alpha augments interleukin-2 production by a direct action on the activated IL-2-producing T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Role of interferon in lymphocyte recruitment into the skin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The double-stranded RNA-dependent protein kinase PKR: structure and function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Inhibitory effect of interferon on the production of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Effect of human lymphoblastoid interferon on insulin synthesis and secretion in isolated human pancreatic islets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Differential responsiveness to interferon-alpha in beta-cells and non-beta cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Suppression of mitochondrial mRNA levels and mitochondrial function in cells responding to the anticellular action of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Inhibition of mitochondrial function by interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferons suppress mitochondrial gene transcription by depleting mitochondrial transcription factor A (mtTFA)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Mitochondrial signals in glucose-stimulated insulin secretion in the beta cell

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Alpha-interferon suppresses food intake and neuronal activity of the lateral hypothalamus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Glutamate neurotoxicity, oxidative stress and mitochondria.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Mitochondrial DNA disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

beta-Cell death during progression to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The role of insulin resistance in the natural history of type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Evidence for peripheral impaired glucose handling in patients with connective tissue diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Failure to detect genomic viral sequences in pancreatic tissues from two children with acute-onset diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Recombinant human Dnase I (rhDNase) in patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Treatment of lupus with corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Inhibition by glucocorticosteroid hormones of interferon and prostaglandin E induction by poly(rI). Poly(rC)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interleukin‐4 Down‐Regulates Sendai Virus‐Induced Production of Interferon‐α and ‐β in Human Peripheral Blood Monocytes In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Antiviral activities of the soluble extracellular domains of type I interferon receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Prolonged allograft survival in cynomolgus monkeys treated with a monoclonal antibody to the human type I interferon receptor and low doses of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Interferon-alpha in tumor immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Endogenous type I interferons as a defense against tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

High-titer interferon-alpha antibodies in a patient with pemphigus foliaceus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Presence of interferon and anti-interferon in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

Viral-Induced Leukocyte Interferon in Vesicle Fluid from Lesions of Recurrent Herpes Labialis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900088-6

7 January 2021

10.1016/S1359-6101(02)00088-6

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12651225